Its cheap valuation, strong growth prospects, and massive dividend make it ripe for outsize investment returns.
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease.
PFE's non-COVID drugs and potential contributions from new and newly acquired products have started to drive growth.
Activist investor Starboard Value has sharpened its criticism of Pfizer Inc. PFE, holding the pharmaceutical giant's management accountable for failing to deliver on its promises of innovation and growth.
Starboard took aim at Pfizer in another blow Tuesday, saying the company has failed to deliver on what it called the "best pipeline" ever.
Activist hedge fund Starboard has taken a stake in drug giant Pfizer. Starboard execs met with company officials last week to outline their complaints.
Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jeff Smith, Starboard Value CEO, joins CNBC's 'Squawk on the Street' to discuss how he sees Pfizer going forward, potential for growth in Kenvue, and more.
Hedge funds managed by Israel Englander and Ken Griffin both scooped up shares in a troubled pharmaceutical stock last quarter.
Starboard has a $1 billion stake in Pfizer and an unknown but "sizable" stake in Kenvue, according to earlier media reports.
Pfizer (PFE) reachead $28.93 at the closing of the latest trading day, reflecting a -0.99% change compared to its last close.
Income investors have both good and not-so-good options in the healthcare sector.